Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

Trial Details

NCT ID
NCT03808337
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Stereotactic Body Radiotherapy/SBRT
  • Systemic Therapy/Standard of Care
Locations (sample)
  • San Carlos, California, United States|37.50716,-122.26052
  • Hartford, Connecticut, United States|41.76371,-72.68509
  • Norwalk, Connecticut, United States|41.1176,-73.4079
  • Miami, Florida, United States|25.77427,-80.19366
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932

Key Eligibility Criteria

  • Metastatic disease detected on imaging and histologically confirmed
  • Metastatic breast cancer (all subtypes)
  • Non-small cell lung cancer (NSCLC) without known targetable molecular alterations in EGFR, ALK, or ROS1
  • NSCLC with EGFR, ALK, or ROS1 targetable molecular alterations who had a history of disease progression on first-line tyrosine kinase inhibitor

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →